drugset / Trial / NCT00932152

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

NCT00932152

Phase 2 Terminated 3 enrolled University of Pittsburgh
RandomizedParallel-groupOpen-labelTreatment

Summary

This research study will test whether dual anti-estrogen therapy (anastrozole and fulvestrant) slows the time to when the cancer progresses.

Timeline

Start
2010-09
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral
Subject Bevacizumab Monoclonal antibody 15 mg/kg Intravenous
Subject Fulvestrant Small molecule 250 mg Intramuscular